Gyre Therapeutics GYRE
NASDAQ GYRE
$6.86 +0.42 (+6.52%)
At close: Sep 4, 2026 · 4:00 PM EDT

Gyre Therapeutics (GYRE) EBIT Margin Growth (5y) (2015 - 2026)

Analysis

Gyre Therapeutics (GYRE) EBIT Margin Growth (5y) (2015 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Gyre Therapeutics 691.38 Mn 633.98 Mn 26.90 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 170,984.00
Mar 31, 2026 148,797.00
Dec 31, 2025 92,799.00
Sep 30, 2025 182,557.00
Jun 30, 2025 103,957.00
Mar 31, 2025 4,127.00
Mar 31, 2023 11.13 Mn
Dec 31, 2022 181,089.00
Mar 31, 2022 -31,240.00
Dec 31, 2021 651,961.00
Sep 30, 2021 414,298.00
Jun 30, 2021 274,999.00
Mar 31, 2021 266,498.00
Dec 31, 2020 336,866.00
Sep 30, 2020 176,131.00
Jun 30, 2020 -79,088.00
Mar 31, 2020 42,022.00
Mar 31, 2018 -11.11 Mn
Dec 31, 2017 92,291.00
Sep 30, 2017 -79,400.00